<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835324</url>
  </required_header>
  <id_info>
    <org_study_id>ChineseAcademyMedicalSciences</org_study_id>
    <nct_id>NCT04835324</nct_id>
  </id_info>
  <brief_title>Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study</brief_title>
  <official_title>Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Hebei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, retrospective, real-world study. The purpose of this study is to&#xD;
      observe the effectiveness and safety of regorafenib in Chinese advanced colorectal cancer&#xD;
      patients.&#xD;
&#xD;
      The main observational goals include overall survival(OS), 6 month OS rate, 1 year OS rate,&#xD;
      and treatment time failure (TTF), other study goals include objective response rate(&#xD;
      ORR)、Disease control rate（DCR）and adverse event(AE) of regorafenib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>6-month Overall Survival rate</measure>
    <time_frame>6 month</time_frame>
    <description>6 months OS rate of patients who received regorafenib treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1 year Overall Survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>1 year OS rate of patients who received regorafenib treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>overall survival of patients who received regorafenib treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>1 year</time_frame>
    <description>Investigator assessed according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>1 year</time_frame>
    <description>Investigator assessed according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients with AE, treatment-related AE (TRAE), AE of special interest (AESI), serious adverse event (SAE) assessed by CTCAE v5.0.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        About 1000 patients in this observational study were recruited in 10 Chinese medical&#xD;
        centers since July 2017 to October 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with colorectal cancer confirmed by pathological tissue or cytology；&#xD;
&#xD;
          2. The pathological type of colorectal tumor was adenocarcinoma；&#xD;
&#xD;
          3. Patients with recurrent or metastatic, unresectable advanced colorectal cancer；&#xD;
&#xD;
          4. Patients who received regorafenib at least one period treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients participating in other interventional clinical studies while taking&#xD;
             regorafenib;&#xD;
&#xD;
          2. Patients with other malignant tumors within 5 years before regorafenib treatment,&#xD;
             except for cured cervical carcinoma in situ, skin squamous cell carcinoma or basal&#xD;
             cell carcinoma, early papillary thyroid carcinoma, etc.;&#xD;
&#xD;
          3. The investigator deems that there are other factors that are not suitable for patients&#xD;
             who participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunbo Zhao</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liangjun Zhu</last_name>
    <role>Study Chair</role>
    <affiliation>Jiangsu Cancer Institute &amp; Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zimin Liu</last_name>
    <role>Study Chair</role>
    <affiliation>The Affiliated Hospital of Qingdao University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Bai</last_name>
    <role>Study Chair</role>
    <affiliation>Shanxi Provincial Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aimin Zang</last_name>
    <role>Study Chair</role>
    <affiliation>Affiliated Hospital of Hebei University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Liu</last_name>
    <role>Study Chair</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Zong</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shengmian Li</last_name>
    <role>Study Chair</role>
    <affiliation>The fourth hospital of Hebei medical university and hebei cancer hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiujuan Qu</last_name>
    <role>Study Chair</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aiping Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer hospital Chinese academy of medical science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aiping Zhou, MD</last_name>
    <phone>13691161998</phone>
    <email>zhouap1825@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital,Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiping Zhou</last_name>
      <phone>13691161998</phone>
      <email>zhouap1825@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiping Zhou, Doctor</last_name>
      <phone>+86 13691161998</phone>
      <email>zhouap1825@126.com</email>
    </contact>
    <investigator>
      <last_name>Aiping Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Aiping Zhou</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

